CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase

Analytical Biochemistry

Volumn 442, Issue 1, 2013, Pages 104-106

  Lynch, James T ^a   Cockerill, Mark J ^a   Hitchin, James R ^a   Wiseman, Daniel H ^a   Somervaille, Tim C P ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Acute myeloid leukemia; Assay; Biomarker; CD86; Inhibitors; LSD1

Indexed keywords

AMINO ACIDS; ASSAYS; BIOMARKERS; CELL MEMBRANES; CORROSION INHIBITORS; DISEASES; POLYMERASE CHAIN REACTION;

ACUTE MYELOID LEUKEMIA; CD86; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTONE DEMETHYLASE LSD1; LSD1; PHARMACOLOGICAL INHIBITION; QUANTITATIVE POLYMERASE CHAIN REACTION; TRANSCRIPTOME ANALYSIS;

ENZYME INHIBITION;

BIOLOGICAL MARKER; CD86 ANTIGEN; CELL SURFACE MARKER; HISTONE DEMETHYLASE; LYSINE SPECIFIC DEMETHYLASE 1; MESSENGER RNA; TRANSCRIPTOME; TRANYLCYPROMINE DERIVATIVE; UNCLASSIFIED DRUG; CD86 PROTEIN, HUMAN; ENZYME INHIBITOR; KDM1A PROTEIN, HUMAN; TRANYLCYPROMINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; UPREGULATION;

ANTIGENS, CD86; BIOLOGICAL MARKERS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HISTONE DEMETHYLASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; STRUCTURE-ACTIVITY RELATIONSHIP; TRANYLCYPROMINE; UP-REGULATION;

EID: 84883450643     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2013.07.032     Document Type: Article

References (13)

1. J.T. Lynch, W.J. Harris, T.C. Somervaille, LSD1 inhibition: a therapeutic strategy in cancer?, Expert Opin Ther. Targets 16 (2012) 1239-1249.
2. Y. Shi, F. Lan, C. Matson, P. Mulligan, J.R. Whetstine, P.A. Cole, R.A. Casero, Histone demethylation mediated by the nuclear amine oxidase homolog LSD1, Cell 119 (2004) 941-953. (Pubitemid 40037608)
3. E. Metzger, M. Wissmann, N. Yin, J.M. Muller, R. Schneider, A.H. Peters, T. Gunther, R. Buettner, R. Schule, LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription, Nature 437 (2005) 436-439. (Pubitemid 41613508)
4. P. Kahl, L. Gullotti, L.C. Heukamp, S. Wolf, N. Friedrichs, R. Vorreuther, G. Solleder, P.J. Bastian, J. Ellinger, E. Metzger, R. Schule, R. Buettner, Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence, Cancer Res. 66 (2006) 11341-11347. (Pubitemid 46009965)
5. S. Lim, A. Janzer, A. Becker, A. Zimmer, R. Schule, R. Buettner, J. Kirfel, Lysinespecific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology, Carcinogenesis 31 (2010) 512-520.
6. S. Hayami, J.D. Kelly, H.S. Cho, M. Yoshimatsu, M. Unoki, T. Tsunoda, H.I. Field, D.E. Neal, H. Yamaue, B.A. Ponder, Y. Nakamura, R. Hamamoto, Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers, Int. J. Cancer 128 (2011) 574-586.
7. M.G. Lee, C. Wynder, D.M. Schmidt, D.G. McCafferty, R. Shiekhattar, Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications, Chem. Biol. 13 (2006) 563-567.
8. M. Yang, J.C. Culhane, L.M. Szewczuk, P. Jalili, H.L. Ball, M. Machius, P.A. Cole, H. Yu, Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine, Biochemistry 46 (2007) 8058-8065. (Pubitemid 47051641)
9. D.M. Schmidt, D.G. McCafferty, Trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1, Biochemistry 46 (2007) 4408-4416. (Pubitemid 46559406)
10. N. Guibourt, A. Ortega Nunez, J. Castro-Palomino Laria, Phenylcyclopropylamine derivatives and their medical use, international patent WO2010/084160 (2010).
11. W.J. Harris, X. Huang, J.T. Lynch, G.J. Spencer, J.R. Hitchin, Y. Li, F. Ciceri, J.G. Blaser, B.F. Greystoke, A.M. Jordan, C.J. Miller, D.J. Ogilvie, T.C. Somervaille, The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells, Cancer Cell 21 (2012) 473-487.
12. L. Chen, D.B. Flies, Molecular mechanisms of T cell co-stimulation and coinhibition, Nat. Rev. Immunol. 13 (2013) 227-242.
13. H. Suzuki, A.R. Forrest, E. van Nimwegen, C.O. Daub, P.J. Balwierz, K.M. Irvine, T. Lassmann, T. Ravasi, Y. Hasegawa, M.J. de Hoon, et al., The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line, Nat. Genet. 41 (2009) 553-562.